Patents Assigned to AGENEBIO, INC.
-
Patent number: 11505555Abstract: This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a ?5-containing GABAA receptor agonist (e.g.Type: GrantFiled: December 20, 2017Date of Patent: November 22, 2022Assignee: AGENEBIO, INC.Inventors: Belew Mekonnen, John A. Butera, Jianxing Huang, Hemantbhai Patel
-
Patent number: 11414425Abstract: This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with CNS disorders. It also relates to the use of an ?5-containing GABAA receptor agonist (e.g., an ?5-containing GABAA receptor positive allosteric modulator) in treating cognitive impairment associated with CNS disorders in a subject in need or at risk thereof, including age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI, Age-Associated Memory Impairment, Age Related Cognitive Decline, dementia, Alzheimer's Disease (AD), prodromal AD, PTSD, schizophrenia, bipolar disorder, ALS, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease, autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of an ?5-containing GABAA receptor agonist (e.g.Type: GrantFiled: June 19, 2019Date of Patent: August 16, 2022Assignee: AGENEBIO, INC.Inventors: Belew Mekonnen, John A. Butera, Jianxing Huang, Hemantbhai Patel, Qin Jiang, Robert Jason Herr, Emily Elizabeth Freeman, Nicholas James Mayhew
-
Patent number: 11312721Abstract: This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a ?5-containing GABAA receptor agonist (e.g.Type: GrantFiled: September 22, 2020Date of Patent: April 26, 2022Assignee: AGENEBIO, INC.Inventors: Belew Mekonnen, John A. Butera, Jianxing Huang
-
Patent number: 11160785Abstract: The invention relates to compositions comprising a synaptic vesicle glycoprotein 2A (SV2A) inhibitor in an extended release and an acetylcholinesterase inhibitor (AChEIs). The invention also relates to using such compositions in treating cognitive impairment associated with central nervous system disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism, compulsive behavior, and substance addiction.Type: GrantFiled: March 14, 2014Date of Patent: November 2, 2021Assignee: AgeneBio Inc.Inventor: Gardiner Smith
-
Patent number: 11142529Abstract: This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a a5-containing GABAA receptor agonist (e.g.Type: GrantFiled: May 31, 2019Date of Patent: October 12, 2021Assignee: AGENEBIO, INC.Inventors: Belew Mekonnen, John A. Butera, Jianxing Huang
-
Patent number: 10925834Abstract: This invention relates to novel extended release pharmaceutical compositions of levetiracetam and preparations and characterizations thereof. This invention further relates to using these extended release pharmaceutical compositions of levetiracetam for the treatment of cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof.Type: GrantFiled: May 20, 2016Date of Patent: February 23, 2021Assignee: AgeneBio, Inc.Inventors: Michela Gallagher, Sharon Rosenzweig-Lipson, Elsie Melsopp, Jack Lawrence James
-
Patent number: 10815242Abstract: This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a ?5-containing GABAA receptor agonist (e.g.Type: GrantFiled: June 17, 2016Date of Patent: October 27, 2020Assignee: AgeneBio, Inc.Inventors: Belew Mekonnen, John A. Butera, Jianxing Huang
-
Patent number: 10329301Abstract: This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a ?5-containing GABAA receptor agonist (e.g.Type: GrantFiled: December 19, 2014Date of Patent: June 25, 2019Assignee: AGENEBIO, INC.Inventors: Belew Mekonnen, John A. Butera, Jianxing Huang
-
Patent number: 10159648Abstract: This invention relates to novel extended release pharmaceutical compositions of levetiracetam and preparations and characterizations thereof. This invention further relates to using these extended release pharmaceutical compositions of levetiracetam for the treatment of cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof.Type: GrantFiled: May 20, 2016Date of Patent: December 25, 2018Assignee: AgeneBio, Inc.Inventors: Michela Gallagher, Sharon Rosenzweig-Lipson, Elsie Melsopp, Jack Lawrence James
-
Patent number: 9801879Abstract: This invention relates to pyridazine derivatives, compositions comprising therapeutically effective amounts of those pyridazine derivatives and methods of using those derivatives or compositions in treating central nervous system (CNS) disorders with cognitive impairment that are responsive to agonists of ?5 subunit containing GABAA receptor, e.g., age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia and cancer-therapy-related cognitive impairment.Type: GrantFiled: September 18, 2015Date of Patent: October 31, 2017Assignee: AGENEBIO, INC.Inventor: John A. Lowe, III
-
Publication number: 20170253603Abstract: This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a ?5-containing GABAA receptor agonist (e.g.Type: ApplicationFiled: December 19, 2014Publication date: September 7, 2017Applicant: AGENEBIO, INC.Inventors: Jianxing HUANG, Belew MEKONNEN, John A. BUTERA, Jianxing HUANG
-
Patent number: 9145372Abstract: This invention relates to pyridazine derivatives, compositions comprising therapeutically effective amounts of those pyridazine derivatives and methods of using those derivatives or compositions in treating central nervous system (CNS) disorders with cognitive impairment that are responsive to agonists of ?5 subunit containing GABAA receptor, e.g., age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia and cancer-therapy-related cognitive impairment.Type: GrantFiled: November 15, 2011Date of Patent: September 29, 2015Assignee: AGENEBIO, INC.Inventor: John A. Lowe, III
-
Publication number: 20130237530Abstract: This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating central nervous system (CNS) disorders with cognitive impairment that are responsive to agonists of ?5 subunit containing GABAA receptor, e.g., age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia and cancer-therapy-related cognitive impairment.Type: ApplicationFiled: November 15, 2011Publication date: September 12, 2013Applicant: AGENEBIO, INC.Inventor: John A. Lowe, III
-
Publication number: 20130237545Abstract: This invention relates to pyridazine derivatives, compositions comprising therapeutically effective amounts of those pyridazine derivatives and methods of using those derivatives or compositions in treating central nervous system (CNS) disorders with cognitive impairment that are responsive to agonists of ?5 subunit containing GABAA receptor, e.g., age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia and cancer-therapy-related cognitive impairment.Type: ApplicationFiled: November 15, 2011Publication date: September 12, 2013Applicant: AGENEBIO, INC.Inventor: John A. Lowe, III